Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

11.6%

27 terminated/withdrawn out of 232 trials

Success Rate

79.2%

-7.3% vs industry average

Late-Stage Pipeline

10%

23 trials in Phase 3/4

Results Transparency

2%

2 of 103 completed trials have results

Key Signals

41 recruiting2 with results22 terminated5 withdrawn

Enrollment Performance

Analytics

N/A
80(43.5%)
Phase 2
57(31.0%)
Phase 1
24(13.0%)
Phase 3
22(12.0%)
Phase 4
1(0.5%)
184Total
N/A(80)
Phase 2(57)
Phase 1(24)
Phase 3(22)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (232)

Showing 20 of 232 trials
NCT06827366Not ApplicableRecruiting

Lifestyle Intervention Among Participants of the French Colorectal Cancer Screening Program (LIFE-SCREEN)

Role: lead

NCT04354233Not ApplicableCompleted

A Physical Activity Program to Improve Quality of Life and Reduce Fatigue in Metastatic Breast Cancer

Role: lead

NCT05947136Not ApplicableRecruiting

PASCA-MM Study. Impact of the PASCA (PArcours de Santé au Cours du CAncer) Program on Complications Associated With Multiple Myeloma and/or Its Treatments in the Context of a First Hematopoietic Stem Cell Autograft, in Adults Aged 18 to 70.

Role: lead

NCT07499921Not ApplicableNot Yet Recruiting

Clinical and BIOgical Analyses of RECtal Tumors

Role: lead

NCT07555600Not ApplicableNot Yet Recruiting

Enumeration and Functional Analysis of Circulating Tumor Cells for Homologous Recombination: a Prospective Single-center Study on Advanced/Metastatic Solid Tumors

Role: lead

NCT04011982Recruiting

PATAKESS Protocol : Clinical and Biological Analysis of Exocrine Pancreatic Tumors

Role: lead

NCT06385691Phase 2Recruiting

Study Evaluating the Efficacy of the myDIET Software Tool in the Nutritional Management of Patients With Localized and Resectable Gastric or Esogastric Junction Cancer.

Role: lead

NCT04562623Recruiting

Prospective Study of Immune Alterations in Operable Breast and Ovarian Carcinoma

Role: lead

NCT06692556Phase 3Recruiting

Study of a Strategy Integrating Adjuvant Radiation Therapy Versus Strategy Based on Monitoring in the Treatment of Carcinomas Spinocellular With High Risk of Recurrence

Role: lead

NCT06059014Phase 1Completed

Phase I/II Study Evaluating PSMA Targeted Radionuclide Therapy in Adult Patients With Metastatic Clear Cell Renal Cancer

Role: lead

NCT06706401Phase 3Recruiting

Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma

Role: lead

NCT03841799Recruiting

COLON-IM : Microbiota and Immune Infiltrate in Normal, Dysplastic and Neoplastic Colorectal Tissue

Role: lead

NCT03818061Phase 2Completed

Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck

Role: lead

NCT05152472Phase 2Recruiting

A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments

Role: lead

NCT04116541Phase 2Recruiting

A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.

Role: lead

NCT05605496Phase 2Active Not Recruiting

NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 Immunotherapies

Role: lead

NCT04216953Phase 1Completed

MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma

Role: lead

NCT07146919Phase 1Withdrawn

AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer

Role: lead

NCT07243470Phase 1Recruiting

Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors

Role: lead

NCT05858424Not ApplicableRecruiting

Impact of a Multidisciplinary End-of-treatment Day Hospital on the Quality of Life of Adolescents and Young Adults With Cancer

Role: lead